An analysis of Phase 3 clinical trials comparing anemia outcomes in DD-CKD patients (the ROCKIES, PYRENEES, SIERRAS, and HIMALAYAS studies) found roxadustat to be superior in anemia correction compared with epoetin α. Here, EPO is linked to anemia (phenotype).